Table Filtering
Submissions
GlyTouCan
Glycan Structure Repository
GlyComb
Glycoconjugate Repository
GlycoPOST
Glycomics MS raw data Repository
UniCarb-DR
Glycomics MS Repository for glycan annotations from GlycoWorkbench
Resources Genes Glycoproteins Lectins Glycolipids Glycans Pathways Diseases Organisms
All Resources
Genes / Proteins / Lipids Glycans / Glycoconjugates Glycomes Pathways / Interactions / Diseases / Organisms
Other Information
Release Statistics Download
Tools
SugarDrawer GlycanBuilder Glycan Converters GlycoMaple GlycomeAtlas LM-GlycomeAtlas GALAXY MCAW GlycoSim GRable
Search Tools
Cross Search Glycan Search Publication Search Programmatic Access
Standards Ontologies Notations
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Fatty Acyls
Glycerolipids
Glycerophospholipids
Saccharolipids
Sphingolipids
Displaying entries 3251 - 3275 of 3913 in total
Main Class Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass Formula ▼
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BC03
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • dimeric Lex(d18:1/20:0)
 44261198 2305.192761 C104H184N4O51
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CH03
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
 44261446 2305.192761 C104H184N4O51
Acidic glycosphingolipids Gangliosides LMSP0601CL06
  • Galalpha1-3Galalpha1-3Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-8NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/26:0)
 44262457 2273.202931 C104H184N4O49
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BO08
  • Galbeta1-4GlcNAcbeta1-3(Galalpha1-3Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44261299 2257.208016 C104H184N4O48
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BV08
  • Galalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44261355 2257.208016 C104H184N4O48
Acidic glycosphingolipids Gangliosides LMSP0601CM06
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-8NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/26:0)
 44262465 2257.208016 C104H184N4O48
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AY08
  • Fucalpha1-2Galbeta1-3GlcNAcbeta1-3(Galbeta1-3GlcNAcbeta1-6)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44260811 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504BA08
  • Fucalpha1-2Galbeta1-3GlcNAcbeta1-3(Galbeta1-4GlcNAcbeta1-6)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44260827 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AW08
  • Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44261155 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BD08
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • Lex-9(d18:1/26:1(17Z))
 44261211 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BI08
  • Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44261251 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CL08
  • Galbeta1-4GlcNAcbeta1-3(Fucalpha1-2Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44261483 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CP08
  • Fucalpha1-2Galbeta1-4GlcNAcbeta1-3(Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44261507 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CS08
  • Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
 44261531 2241.213101 C104H184N4O47
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AJ08
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • type III A antigen(d18:1/26:1(17Z))
 44261051 2225.218186 C104H184N4O46
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BP02
  • GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3(Galalpha1-3Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44261301 2350.17784 C104H183N5O53
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BW02
  • Galalpha1-3Galbeta1-4GlcNAcbeta1-3(GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44261357 2350.17784 C104H183N5O53
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505EN02
  • Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • nLcOse10(d18:1/18:0)
 44261829 2350.17784 C104H183N5O53
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504BG02
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3(Galbeta1-3GlcNAcbeta1-6)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44260861 2334.182925 C104H183N5O52
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504BJ02
  • GalNAcalpha1-3Galbeta1-3GlcNAcbeta1-3(Fucalpha1-2Galbeta1-3GlcNAcbeta1-6)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44260885 2334.182925 C104H183N5O52
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CC02
  • GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44261405 2334.182925 C104H183N5O52
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CT02
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44261533 2334.182925 C104H183N5O52
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505EE02
  • Fucalpha1-2(GalNAcalpha1-3)Galbeta1-4GlcNAcbeta1-3(Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44261765 2334.182925 C104H183N5O52
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505EF02
  • GalNAcalpha1-3Galbeta1-4GlcNAcbeta1-3(Fucalpha1-2Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44261773 2334.182925 C104H183N5O52
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505EG02
  • Fucalpha1-2Galbeta1-4GlcNAcbeta1-3(GalNAcalpha1-3Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
 44261781 2334.182925 C104H183N5O52
Download data in CSV format Download data in TSV format Download data in JSON format
About Release Notes Help Feedback

Click here to visit the beta site.

International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01

Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International

GlyCosmos Portal v4.0.0

Last updated: August 19, 2024